Co-Authors
This is a "connection" page, showing publications co-authored by Koen Van Besien and Peter H. O'Donnell.
Connection Strength
1.421
-
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
Score: 0.391
-
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1.
Score: 0.359
-
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT). J Clin Oncol. 2008 May 20; 26(15_suppl):7042.
Score: 0.332
-
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73.
Score: 0.126
-
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1552-7.
Score: 0.108
-
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
Score: 0.106